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Abstract
Background: A few viruses have been detected in prostate cancer, however their role in the development of this
malignancy has not been determined. The aim of this study was to analyze the presence and functionality of
human papillomavirus (HPV) and polyomaviruses (BKPyV and JCPyV) in prostate carcinomas in Chilean patients.
Methods: Sixty-nine primary prostate carcinomas were analyzed for the presence of HPV, BKPyV and JCPyV using
standard polymerase chain reaction protocols. In addition, when samples were positive for HPyV, large T antigen
(TAg) transcripts were analyzed using reverse transcriptase PCR.
Results: HPV and JCPyV were not detected in any specimens (0/69, 0 %); whereas, BKPyV was detected in 6/69
PCas (8.7 %). We did not find a statistically significant association between the presence of BKPyV and age
(p = 0.198) or Gleason score (p = 0.268). In addition, 2/6 (33 %) BKPyV positive specimens showed detectable levels
of TAg transcripts.
Conclusions: There was no association between HPV or JCPyV presence and prostate cancer development. The
presence of BKPyV in a small subset of prostate carcinomas in Chilean patients could indicate that this virus plays a
potential role in prostate cancer development and requires further investigation.
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Introduction
Prostate cancer (PCa) is the second most common can-
cer worldwide [1], and is particularly common in indus-
trialized countries. In Chile, the incidence rate of PCa is
27.9/100,000 inhabitants and its mortality rate is 15.6/
100,000 inhabitants [1]. Human papillomavirus (HPV)
and polyomaviruses (HPyV) are small non-enveloped
DNA viruses that have been detected at variable fre-
quencies in PCas worldwide. However, the etiological
role of these viruses has only been established in specific
tumors. For example, high-risk HPVs are the causal
agent of cervical, anogenital and a subset of oropharyn-
geal carcinomas [2]. In addition, there is convincing evi-
dence that Merkel cell polyomavirus (MCPyV) is the
etiological agent of Merkel cell carcinomas [3]. Although
the DNA of both HPV and HPyV has been detected in
PCas, there is high variability in the detection rates be-
tween different studies. Nevertheless, the mere detection
of viral DNA fragments in clinical specimens is not a
sufficient to indicate causality. Previous reports have de-
scribed the presence of HPV in biopsies of PCa and
prostatic benign hyperplasia [4–8]. However, a recent
meta-analysis concluded that high-risk HPV-16 and −18
did not contribute to increased PCa risk [9]. The re-
ported frequencies of HPyVs, and in particular BKPyV,
in PCas have been inconsistent [10–13]; while other
studies have proposed that BKPyV is not involved in
PCa [14, 15]. JCPyV is the etiologic agent of progressive
multifocal leukoencephalopathy (PML), a neurodegener-
ative disease [16]. It has been suggested that the
presence of JCPyV correlates with various types of hu-
man neoplasm, including colorectal, gastric, prostatic,
oesophageal, brain and bronchial carcinomas and B cell
lymphomas [17]. However, an oncogenic role for this
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virus has not been definitively established. Taken to-
gether, the definitive role of viral infections, such as
HPV, BKPyV and JCPyV, in prostate carcinogenesis has
not been established. Thus the aim of this study was to
determine the presence of HPV, BKPyV and JCPyV in
PCas in patients at two public hospitals in Santiago,
Chile, and to analyze the expression levels of viral onco-
genes in virus-positive PCas samples.
Materials and methods
Clinical samples
For this retrospective study, formalin-fixed and paraffin-
embedded specimens from PCas confirmed by histo-
logical analysis were used. Samples were collected at San
Borja Arriarán Hospital (thirty one samples from 2004
to 2012) and at José Joaquin Aguirre Hospital (thirty
eight samples, from 2005 to 2009) in Santiago, Chile.
The participants did not provide their written or verbal
informed consent to participate in this study. Under
Chilean law, informed consent is not necessary if the
analysis does not pertain to the human genome. Only
viral DNA sequences were analyzed in this study, which
was approved by the Ethics Committee of the José Joa-
quín Aguirre Hospital, Faculty of Medicine, Universidad
de Chile.
DNA extraction and detection of viral infections
Paraffin tissue sections were incubated with digestion
buffer (10 mM Tris–HCl pH 7.4, 0.5 mg/mL proteinase
K and 0.4 % Tween 20) at 37 °C for 3 h. Afterwards, the
samples were incubated for 10 min at 95 °C, centrifuged
for 2 min at 14,000 rpm and immediately placed on ice.
After centrifugation, the aqueous phase was transferred
to a new tube [18].
HPV typing was performed by a type-specific multiplex
genotyping (TS-MPG) assay, which combines multiplex
PCR and bead-based Luminex Technology, as previously
described [19–21]. This assay is able to detect DNA from
19 alpha mucosal HPV types (16, 18, 26, 31, 33, 35, 39, 45,
51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82). In addition,
we used conventional PCR with the GP5+/6+ primers as
an alternative technique for HPV detection. DNA quality
was determined by PCR using the betaglobin gene frag-
ment as a marker with the following primers: PCO3 5′-
ACACAACTGTGTTCACTAGC-3′ and PCO4 5′-CAA
CTTCATCCACGTTCACC-3′. The amplification pro-
gram was as follows: denaturation at 95 °C for 5 min,
45 cycles with a cycling profile of 95 °C for 30 s, 52 °C for
30 s, 72 °C for 30 s and final extension at 72 °C for 5 min.
For HPV amplification we used the following primers:
GP5+ 5′- TTTGTTACTGTGGTAGATATCAC-3′ and
GP6+ 5′- GAAAAATAAACTGTAAATCATATTC-3′.
The PCR conditions were as follows: denaturation at
95 °C for 5 min, 45 cycles with a cycling profile of 95 °C
for 1 min, 52 °C for 2 min, 72 °C for 1.5 min and a final
extension at 72 °C for 5 min. The amplification products
were stained with MasterSafe (Promega), visualized under
UV transillumination and photographed.
BKPyV detection was conducted using qPCR with an
intercalating dye format as previously reported [22].
Briefly, a 127 bp fragment of the BKPyV genome was
amplified with the following BK127-F and BK127-R
primers: BK127-F: 5′-GCA GCT CCC AAA AAG CCA
AA-3′ and BK127-R: 5′-CTG GGT TTA GGA AGC
ATT CTA-3′. The 20 μL final volume reactions con-
tained 1X LightCycler® FastStart DNA Master SYBR
Green I (Roche Diagnostics, Indianapolis, IN, USA),
0.5 μM of each primer, 3.0 μM MgCl2 and 5 μL of DNA
template. The PCR reaction was run for 40 cycles as fol-
lows: denaturation as 94 °C for 10 s, annealing at 62 °C
for 10 s and extension at 72 °C for 10 s, with an initial
denaturation at 95 °C for 15 min and final extension at
72 °C for 10 min. The amplification products were sub-
jected to a melting profile and the specific product was
characterized according to its Tm.
JCPyV was detected using real-time qPCR with JE3




CTACCCCACCTAAAAAGA-BHQ1-3′) according to a
previously described protocol [23, 24]. The PCR reac-
tion contained 1X Brilliant® II QRT-PCR Master Mix
(Agilent Technologies Santa Clara, CA, USA), 0.5 μM
of each primer, 0.15 μM of probe and 5 μL of DNA in a
total volume of 25 μL. The amplification conditions
were as follows: 95 °C for 10 min, followed by 50 cycles
with denaturation at 95 °C for 15 s and annealing/ex-
tension at 60 °C for 1 min. The sensitivity for JCPyV
and BKPyV detections by qPCR was 40 viral copies in
20 μL of reaction mix.
Large T antigen (TAg) transcript detection
RNA purification was carried out using the High Pure
RNA paraffin kit (Roche), following the manufacturers’
instructions. The RNA was suspended in 50 μL of TE
(10 mM Tris-Cl, 1 mM EDTA) and stored at −80 °C
until use. The RNA was incubated for 1 h at 37 °C with
RQ1 DNAse and the enzyme was inactivated by incuba-
tion at 70 °C during 10 min. The cDNA preparation was
made in accordance with the conditions established by
the manufacturer using M-MLV reverse transcriptase
(Promega). Negative controls without M-MLV were in-
cluded. The reaction mixture was incubated at 37 °C for
1 h and stored at −20 °C. We used GAPDH amplifica-
tion as a constitutive expression control, according to a
previously reported protocol [25]. The amplification of
TAg transcripts was carried out using the following
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primers: BKF: 5′-AGC CAC ACC CAG TTC AAA AG-
3′and BKR: 5′-AAA CAA CAC TAG CTG CAG GG-3′.
The 25-μL final volume reactions contained 1X Buffer
(Promega), 0.4 μM of each primer, 1.5 μM MgCl2 and
1 μL of cDNA template. The amplification program was
as follows: initial denaturation at 95 °C for 5 min
followed by 45 cycles consisting of denaturation at 94 °C
for 1 min, annealing at 55 °C for 1 min and extension at
72 °C for 1 min, followed by a final extension at 72 °C
for 5 min. The amplification products (98 bp) were
stained with MasterSafe (Promega), visualized under UV
transillumination and photographed.
Statistical analysis
Statistical analysis was performed using the Fisher’s
exact test with the Stata 13.0 software. A p-value of less
than 0.05 was considered statistically significant.
Results
In this study we determined the presence of HPV,
BKPyV and JCPyV in PCas in Chilean patients. Sixty-
nine PCa samples obtained from patients at two public
hospitals in Santiago, Chile were selected. Table 1 shows
the clinical-pathological characteristics of patients in-
cluded in this study. The mean age was 63 ± 6 years and
the mean Gleason score of the tumors was 6.98 ± 1.10,
with a range of 2 to 9. Age did not differ between the
two hospitals (p = 0.336). However, we found that the
Gleason score was significantly different between the
two hospitals; patients treated at the J. J. Aguirre Hos-
pital had a higher Gleason score compared to patients
treated at the Barros Luco Hospital (p = 0.006).
Amplification of a 110 bp fragment of b-globin gave a
similar yield in all samples. Using a highly sensitive
genotyping assay (TS-MPG), HPV genomes were not de-
tected in any of the samples. In addition, the absence of
HPV genomes in all samples was confirmed by an inde-
pendent GP5+/6+ PCR assay [26]. In contrast, for polyo-
maviruses we found that 6/69 (8.7 %) samples were
positive by qPCR for BKPyV. Table 2 shows BKPyV de-
tection and its association with clinical-pathological
features. No statistically significant differences were
found between age (p = 0.198), Gleason score (p = 0.268)
or hospital (p = 0.402) and BKPyV presence in PCa. The
dissociation curves for BKPyV and melting analysis of
BKPyV positive and negative cases are shown in the
Fig. 1.
Finally, we determined the expression of the TAg at
the RNA level in BKPyV positive cases. Table 3 shows
the expression of TAg in BKPyV positive cases along
with hospital, age and Gleason score.
Discussion
PCa is a biologically heterogeneous tumor affecting men
that involves multiple factors in its etiology [27]. Several
risk factors for PCa have been identified, such as age, fa-
miliar history, ethnicity, diet and environment [28]. In
addition, molecular alterations involved in PCa develop-
ment have been well characterized, and some alterations
in specific pathways have been identified, such as the an-
drogen receptor pathway, phosphatidyl inositol 3-kinase
(PI3K) and functional loss of the prostate tumor sup-
pressor NKX3.1, among others [29]. In this context, the
potential role of HPV or HPyVs infections in the devel-
opment of this malignancy has been investigated previ-
ously. It must be mentioned that in order to establish a
causal relationship between HPV or HPyVs and PCa de-
velopment, some questions need to be answered. First, is
it biologically possible for HPV or HPyVs to be involved
in prostate cancer development? In this respect, Choo et
al. were able to immortalize prostate epithelial cells with
HPV-16 E6/E7 oncogenes [30], and earlier experimental
in vitro approaches demonstrated that HPV in collabor-
ation with Ki-ras activation was able to transform pros-
tate cells, raising the possibility of HPV-mediated
oncogenicity [31]. It has also been suggested that BKPyV
is a cofactor for PCa in its early stages, which is in agree-
ment with the low occurrence of pRb and Rb1 mutations
[12]. Moreover, BKPyV is oncogenic in hamster and
mouse cells, where the continuous expression of a
Table 1 Clinical and pathological characteristics of study
patients by hospital
Number of subjects (%)
J. J. Aguirre Barros Luco p-value
Total 38 (100) 31 (100)
Age <65 21 (55.3) 13 (41.9) 0.336
≥65 17 (44.7) 18 (58.1)
Gleason Low 7 (18.4) 17 (54.8) 0.006*
Medium 20 (52.6) 8 (25.8)
High 11 (29.0) 6 (19.4)
*Indicates a statistically significant difference by hospital
Table 2 BKPyV presence in prostate cancer in relation to
clinical-pathological features
Number of subjects (%)
BKPyV (−) BKPyV (+) p-value
Total 63 (100) 6 (100)
Age <65 33 (52.4) 1 (16.7) 0.198
≥65 30 (47.6) 5 (83.3)
Gleason Low 22 (34.9) 2 (33.3) 0.268
Medium 27 (42.9) 1 (16.7)
High 14 (22.2) 3 (50.0)
Hospital Barros Luco 27 (42.9) 4 (66.7) 0.402
José J. Aguirre 36 (57.1) 2 (33.3)
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functional TAg is required [32]. Thus, it seems biologic-
ally possible that both viruses may be able to transform
prostate cells and could potentially be involved in pros-
tate carcinogenesis. The second question is: Is this bio-
logical relationship epidemiologically important to PCa
development? This is a controversial topic for the rea-
sons mentioned previously. In particular, the reported
rate of HPV infection in PCa varies worldwide [9], and
specifically it has been suggested that the male genital
tract or the sperm may be a reservoir for the presence of
this virus [33]. The role of HPV in PCa development has
been evaluated in many studies [9]; however, findings
have been inconclusive [34]. In the present study, using
two different PCR-based approaches we were not able
not detect HPV DNA sequences in PCa samples. Al-
though our results suggest that HPV is probably not re-
lated to this malignancy, we cannot strictly rule out a
“hit and run” mechanism, as has been previously sug-
gested for the HPV-18 genotype [35]. JCPyV has previ-
ously been reported in benign prostate hyperplasia
(BPH) and in PCa, suggesting that it is probably a by-
stander infection in the prostate [10]. Moreover, it was
reported that JCPyV was frequently present in normal
prostate specimens, suggesting that this virus replicates
in the prostate epithelium [36]. In this study we were
not able to detect JCPyV infection in any of the PCa
specimens, suggesting that this virus is not related to the
development of this disease. BKPyV was detected in
8.7 % of PCa specimens, and 33 % of BKPyV positive
specimens expressed the TAg. It has been previously
Fig. 1 Dissociation curves and melting analysis of BKPyV positive and negative cases. The observed Tm was 80.8ºC.
Table 3 Large T antigen expression and clinical features for
BKPyV positive prostate cancers
Patient Hospital Age Gleason TAg
1 BL 65 6 -
2 BL 65 7 -
3 JJA 67 8 +
4 JJA 57 8 -
5 BL 67 8 +
6 BL 68 6 -
BL Barros-Luco Hospital, JJA José Joaquín Aguirre Hospital
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reported that this oncoprotein is able to bind and inacti-
vate pRb and p53 tumor suppressor proteins, frequently
downregulated in cancer, and specifically in viral-
induced tumors [37]. Thus our results suggest that in
the 33 % of BKPyV positive cases an oncogenic role of
BKPyV is plausible. However, the limitations of this
study are that our methodological approach does not
allow us to determine if the viral infection is present in
each tumor cell, as the original specimen contains adja-
cent non-tumor cells. The use of microdissection or in
situ methodological approaches will be necessary in fu-
ture studies.
Given our findings, a third question arises: Is the
presence of BKPyV in PCa clinically relevant? In this
respect, it is plausible that the presence of oncogenic
viruses with functional activity is related to changes in
the behavior of the tumor, and consequently be related
to clinical observations. It has been previously estab-
lished that patients positive for high-risk HPV with
oropharyngeal carcinomas have better outcomes and
higher rates of survival compared to HPV negative pa-
tients [38]. However, such a relationship for viral infec-
tions in the prostate, and specifically for BKPyV, has
not been established. In our study we did not find a sta-
tistically significant association between BKPyV infec-
tion and age, even though 87 % of BKPyV infections
were detected in subjects over 65 years of age. This
finding is compatible with the reactivation of this virus
in the elderly or those under immunosuppressed condi-
tions. In addition, 50 % of BKPyV positive patients
showed a high Gleason score as compared to 22 % of
BKPyV negative patients, although this difference was
not statistically significant. Although this virus is ac-
quired in early childhood, the transmission route is un-
known, but is likely through oral or gastrointestinal
mucosa, and disseminated into the kidneys where the
virus develops a persistent infection [39, 40]. In this re-
spect it has been suggested that rearranged noncoding
control regions (NCCRs) of polyomaviruses altering the
number and composition of transcription factor bind-
ing sites (TFBSs) are involved in silent persistence and
reactivation [41]. In addition, it has been reported that
BKPyV downregulates Toll like receptor 9 (TLR9) rais-
ing the possibility that such downregulation is involved
in viral persistence [42]. In fact, it was established that
90 % of the population is serologically positive for
BKPyV infection [43].
In conclusion, in this study we determined that
BKPyV was present in a discrete number of prostate
cancers in Chilean patients, with partial detection of
TAg antigen in BKPyV positive specimens, suggesting a
causal association in a subset of cases. More studies are
warranted to elucidate the clinical significance of these
findings.
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